Group 1 - The core point of the report is that Hunan Sailoxian Management Consulting Partnership (Limited Partnership) has acquired 58,606,962 shares of Qidi Pharmaceutical Group Co., Ltd., representing 24.47% of the total shares, through judicial auction, making it the controlling shareholder of the company [1][18][24] - The acquisition was executed following a court ruling and was completed on August 5, 2025, with the total payment amounting to 1,007.39 million yuan [20][19] - The report confirms that the acquisition does not aim to terminate the listing status of Qidi Pharmaceutical and that the company will continue to operate independently [17][23] Group 2 - Hunan Sailoxian was established on June 19, 2025, primarily engaged in investment management, with a registered capital of 405.57 million yuan [4][6] - The actual controller of Hunan Sailoxian is Jiang Lin, who holds 66.86% of the shares in the executing partner, Shanghai Sailoxian [5][6] - Qidi Pharmaceutical operates in the pharmaceutical manufacturing industry, focusing on the research and development of traditional Chinese medicine and Western medicine formulations, with over 140 drug varieties and more than 30 patents [24][25] Group 3 - The financial data of Shanghai Sailoxian shows total assets of 1,650.71 million yuan and total equity of 1,322.98 million yuan as of December 31, 2024, with a net profit of 93.54 million yuan [6][13] - The report indicates that there are no significant legal violations or administrative penalties against Hunan Sailoxian in the past five years [14][16] - The report outlines that there is a potential for competition between Qidi Pharmaceutical and Hunan Sailoxian's core enterprise, Hengchang Pharmaceutical, due to overlapping product lines [24][26]

Core Viewpoint - The financial advisor, CITIC Securities, has verified the detailed equity change report of Tsinghua Unigroup Pharmaceutical Group Co., Ltd., confirming that the disclosed information is accurate, complete, and compliant with relevant laws and regulations [1][5][21]. Group 1: Overview of the Equity Change - The equity change involves the acquisition of 58,606,962 shares of Tsinghua Unigroup, representing 24.47% of the total share capital, making the acquirer the controlling shareholder [16][17]. - The acquisition was executed through a judicial auction, with the total payment amounting to 1,007.39 million yuan [21][22]. Group 2: Financial Status of the Acquirer - The acquirer, Hunan Sailoxian Management Consulting Partnership (Limited Partnership), was established on June 19, 2025, with a registered capital of 405.57 million yuan [5][6]. - The financial data of the acquirer shows total assets of 1,650.71 million yuan and total equity of 1,322.98 million yuan as of December 31, 2024 [13]. Group 3: Impact on Tsinghua Unigroup - Tsinghua Unigroup will maintain its independence as a listed company, with no plans to change its main business or make significant adjustments in the next 12 months [22][24]. - The acquirer has committed to avoiding any actions that would harm the interests of Tsinghua Unigroup and its minority shareholders [25][29]. Group 4: Compliance and Regulatory Aspects - The acquirer has adhered to all necessary legal procedures and obligations regarding the equity change, including the commitment to disclose any future changes in shareholding [16][22]. - There are no reported violations or legal issues concerning the acquirer in the past five years [14][15].